Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss

Am J Hematol. 2019 Oct;94(10):E273-E275. doi: 10.1002/ajh.25591. Epub 2019 Aug 13.

Affiliations

¹ Department of Medicine, University of Maryland School of Medicine and Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.
² Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland.
³ Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.

PMID: 31342556
DOI: 10.1002/ajh.25591

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenine / analogs & derivatives
Antibodies, Monoclonal, Humanized / administration & dosage
Antigens, CD19 / administration & dosage
Antigens, CD19 / immunology*
Antigens, CD19 / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Benzamides / administration & dosage
Biological Products
Combined Modality Therapy
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Fatal Outcome
Female
Humans
Immunotherapy, Adoptive*
Isoindoles / administration & dosage
Lymphocyte Depletion
Lymphoma, B-Cell / drug therapy
Lymphoma, B-Cell / immunology
Lymphoma, B-Cell / therapy*
Lymphoma, Follicular / drug therapy
Male
Middle Aged
Neoplasms, Multiple Primary / drug therapy
Piperidines
Prednisone / administration & dosage
Pyrazoles / administration & dosage
Pyrimidines / administration & dosage
Recurrence
Salvage Therapy
Vincristine / administration & dosage

Substances

Antibodies, Monoclonal, Humanized
Antigens, CD19
Benzamides
Biological Products
CD19 molecule, human
Isoindoles
Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Vincristine
Doxorubicin
Cyclophosphamide
pembrolizumab
Adenine
(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone
axicabtagene ciloleucel
Prednisone

Supplementary concepts

CHOP protocol